Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MRTX exchanges : Nasdaq save search
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | $3.79 -0.78% 0.0% 1K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
CORT M | $23.0 -1.67% -1.7% 960K
|
Health Technology
|
| O: 0.6%
H: 2.48%
C: 2.48%
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
|
| O: -0.07%
H: 1.38%
C: 1.25%
EVR | $185.5 0.45% 0.0% 360K
|
Finance
|
| O: 0.35%
H: 0.29%
C: -0.26%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | $285.11 3.83% 420
|
Health Technology
|
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB | $28.51 -3.13% -3.23% 360K
|
Health Technology
|
| O: 7.35%
H: 0.44%
C: -2.18%
results
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.38%
KURA | $18.0 -3.17% -3.28% 660K
|
Health Technology
|
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806 collaboration therapeutics agreement
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | $3.79 -0.78% 0.0% 1K
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.04%
H: 0.35%
C: -0.53%
lung cancer cell results
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.68 0.0% 100K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Published: 2023-09-10 (Crawled : 04:20) - prnewswire.com
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
| Email alert
Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
lung conference world cancer response study
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-09-05 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.36%
H: 0.86%
C: -1.17%
nasdaq grant therapeutics
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-08-29 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
|
| O: 1.44%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.69%
H: 1.04%
C: 1.01%
conference global therapeutics
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.5%
H: 1.29%
C: -1.02%
lung conference world cancer results study
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2023-08-11 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering - August 09, 2023
Published: 2023-08-09 (Crawled : 11:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering
Published: 2023-08-09 (Crawled : 05:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Published: 2023-07-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -2.19%
therapeutics report financial results
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.